Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Dianthus Therapeutics' DNTH103 is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing ...

A redefining rebrand for CRO Antibody Analytics as it announces plans for future growth7th October 24 - RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, will give the opening ceremony keynote, “Innovating for Impact: How ...

A copy of the posters and presentation will be available on the company’s website following the conference.

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation ...

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a ...